Publications
Open-Label, Multicenter, Phase I/II, First-in-Human Trial of TK216: A First-Generation EWS::FLI1 Fusion Protein Antagonist in Ewing Sarcoma
Journal of Clinical Oncology
An EWS::FLI1 monoclonal antibody with multimodal utility and specificity for FLI1
Saravana Selvanathan, Jeffrey Toretsky (2023)
bioRxiv
Comprehensive profiling of mRNA splicing indicates that GC content signals altered cassette exon inclusion in Ewing sarcoma
Clofarabine induces ERK/MSK/CREB activation through inhibiting CD99 on Ewing sarcoma cells
PLoS One
Ewing Sarcoma—Diagnosis, Treatment, Clinical Challenges and Future Perspectives
Ewing Sarcoma
Development of an Ewing sarcoma cell line with resistance to EWS‑FLI1 inhibitor YK‑4‑279
Mol Med Rep
The ETS Inhibitors YK-4-279 and TK-216 Are Novel Antilymphoma Agents
Clinical Cancer Research
EWS–FLI1 modulated alternative splicing of ARID1A reveals novel oncogenic function through the BAF complex
Nucleic Acids Res.